Information regarding Coronavirus disease 2019 in the transplant population is lacking. Recently it has been suggested that cycle threshold values obtained on polymerase chain reaction tests may serve as a marker of disease severity with lower values (i.e., higher viral load) being associated with higher mortality. This study was done to assess the impact of remdesivir use on the time to a negative COVID-19 PCR as well as the degree of change between two Ct’s based on treatment. A total of 30 kidney transplant patients with a new diagnosis of COVID-19 were assessed. Serial PCR results were followed from the time of diagnosis then every 2–4 weeks until negative. In patients who received remdesivir immediately after COVID-19 confirmation compared to no remdesivir, time to negative PCR was not statistically different with a median duration of 57 days in both groups (p = 0.369). The change in the Ct between the first and the second PCR test was also not statistically different between groups with a median change of 18.4 cycles in the remdesivir group and 15.7 cycles without remdesivir (p = 0.516). The results of this small single-center analysis suggest that remdesivir may not be beneficial in shortening time to a negative COVID-19 PCR.

No abstract

No abstract

To the Editor, Cytomegalovirus (CMV) infections cause significant morbidity and mortality among all solid organ transplant recipients. CMV discordant (D+/R−) recipients are at higher risk of developing CMV viremia after cessation of prophylaxis. 1 CMV-specific T-cell-mediated immunity (CMI) has been shown in previous studies to predict those at the highest risk for CMV-associated events. 2-4 However, it is unknown if changes in maintenance immunosuppression guided by CMI may lead to fewer CMV events as a result of improved immunity.